Compare BLNK & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLNK | DCTH |
|---|---|---|
| Founded | 2009 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 86.2M | 578.4M |
| IPO Year | 2008 | 2015 |
| Metric | BLNK | DCTH |
|---|---|---|
| Price | $0.59 | $16.14 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $2.33 | ★ $22.00 |
| AVG Volume (30 Days) | ★ 1.1M | 346.4K |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 61.22 | ★ 107.53 |
| EPS | N/A | ★ 0.04 |
| Revenue | ★ $126,197,000.00 | N/A |
| Revenue This Year | $5.71 | $24.54 |
| Revenue Next Year | $19.65 | $33.15 |
| P/E Ratio | ★ N/A | $402.75 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.45 | $8.12 |
| 52 Week High | $2.65 | $17.42 |
| Indicator | BLNK | DCTH |
|---|---|---|
| Relative Strength Index (RSI) | 56.87 | 52.24 |
| Support Level | $0.57 | $15.68 |
| Resistance Level | $0.62 | $16.51 |
| Average True Range (ATR) | 0.03 | 0.40 |
| MACD | 0.00 | -0.13 |
| Stochastic Oscillator | 77.00 | 37.69 |
Blink Charging Co is an owner, operator, and provider of electric vehicle (EV) charging services. The company offers both residential and commercial EV charging equipment, enabling EV drivers to easily recharge at various location types. The Blink's principal line of products and services is its Blink EV charging networks, Blink EV charging equipment, and other EV-related services. The Blink Network is a proprietary, cloud-based system that operates, maintains, and manages Blink charging stations and handles the associated charging data, back-end operations, and payment processing. The Blink Network provides fleets, property owners, managers, parking companies, and state and municipal entities, among other types of commercial customers, with cloud-based services.
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.